24 October 2018 - The Institute for Clinical and Economic Review today announced that it will not proceed with its comparative clinical effectiveness and value assessment of canakinumab. 

This decision is the result of the FDA recently issuing a complete response letter to Novartis Pharmaceuticals, declining to approve canakinumab’s expanded indication for atherosclerotic cardiovascular disease.

In June 2018, ICER originally announced its intention to assess canakinumab. With the termination of this assessment, ICER is also canceling the February 2019 public meeting of the California Technology Assessment Forum, which was scheduled to review ICER’s evidence report and develop recommendations for how stakeholders could apply the evidence on canakinumab to improve the quality and value of cardiovascular health care.

Read ICER announcement